Nelarabine Completed Phase 2 Trials for Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00003545506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00003635506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
NCT00006020S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia